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Dose–responsea b s t r a c t
There is currently no standard method for delineating the oral mucosa and most attempts are
oversimpliﬁed. A new method to obtain anatomically accurate contours of the oral mucosa surfaces
was developed and applied to 11 patients. This is expected to represent an opportunity for improved
toxicity modelling of oral mucositis.
 2015 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 115 (2015) 63–66
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Mucositis of the oral mucosa is a common and important acute
toxicity in head and neck radiotherapy warranting efforts to
mitigate its severity and impact on patients. It may result in
reduced quality of life due to pain, dysphagia [1–3], weight loss
and aspiration [4,5]. These effects can result in patients being
hospitalised and missing treatment fractions [6], compromising
locoregional control [7,8]. Mucositis is also frequently the dose-
limiting toxicity in dose escalation and accelerated fractionation
regimens, designed to improve tumour control [9–11], and has
been implicated in causing ‘late’ toxicity [12–15].
Heterogeneous dose distributions are delivered to the mucosa
with intensity-modulated radiotherapy (IMRT), allowing the oral
mucosa to be partially spared [16]. However, the development
and grade of mucositis is challenging to predict. If a relationship
between the dose distribution and toxicity is established, it may
be possible to reduce oral mucositis, by means of a treatment
planning intervention. Few dose–response studies have been
performed for oral mucositis. The complex shape of the mucosal
surface, coupled with the fact that it is poorly visualised on com-
puted tomography (CT) are challenges to accurate delineation.
Previous oral mucosa dose–response studies [16–18] have reduced
the complex shape of the oral mucosa surfaces to a solid oral cavity
volume. Clinical experience suggests that dose–area effects may
inﬂuence mucositis severity. Characterising the dose delivered tothe surfaces of the oral mucosa is necessary to properly study
the dose–response relationship. A method of obtaining the dose
distribution delivered to the oral mucosa surfaces would, therefore,
represent an important advance in attempts to model and, thereby,
reduce oral mucositis.
The primary aim of this study was to develop CT-based
delineation guidelines to contour the surfaces of the oral mucosa
in an anatomically realistic manner. The secondary aim was to
establish the worth of the new contouring approach for dose–
response studies by assessing the magnitude of the differences in
dose metrics extracted from treatment plans using the new, more
realistic approach, and previously used contouring techniques.Materials and methods
Patients
Treatment plans of 11 head and neck radiotherapy patients
treated at our institution between 2006 and 2013 were included
in the study. The patients had oral cavity contours (OCC) generated
using our previous method [17] (based on the oral mucosa
deﬁnition described by Eisbruch et al. [19]), and these were used
for comparison of the dose distributions extracted using our new
technique for obtaining mucosal surface contours (MSC). This
cohort incorporated a range of primary disease sites (oropharynx,
hypopharynx and nasopharynx), two different CT scanners and
included edentulous and dentate patients, eight of whom had
dental implants.
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The MSC were deﬁned as a 3 mm thick wall of tissue based on
work by Ueno et al. measuring the oral mucosal thickness at multi-
ple sites in ﬁve cadavers using a reamer method [20]. They mea-
sured a mean thickness of 3.12 ± 1.43 mm. The outlined MSC
included the following surfaces: buccal mucosa, buccal gingiva,
gingiva proper, lingual gingiva, lingual frenulum, alveolar mucosa,
labial mucosa, labial gingiva, labial frenulum, mucosal surface of
the ﬂoor of mouth, mucosal surface of the tongue anterior to the
terminal sulcus, and the mucosal surface of the hard palate. The
superior extent was deﬁned to be the superior border of the labial
mucosa of the upper lip anteriorly, the roof of the palate posteri-
orly and the superior extent of the buccal mucosa laterally. The
inferior extent was formed by the inferior border of the labial
mucosa of the lower lip anteriorly, the surface of the tongue
posteriorly and the inferior extents of the ﬂoor of mouth mucosa
and buccal mucosa laterally. The lateral extents of the buccal
mucosa formed the lateral borders. The anterior border followed
the alveolar mucosa and the posterior extent of the hard palate
formed the posterior border (Fig. 1).Structure delineation
Structure delineation was performed, by a head and neck radia-
tion oncologist (LW), using the RayStation version 4.0 treatmentFig. 1. CT scan of a head and neck radiotherapy patient with the OCC (top) and MSC (b
mucosal wall to a simpliﬁed solid volume, whereas the MSC structure is represented as a
the oral mucosa.planning system (RaySearch Laboratories AB, Stockholm,
Sweden). The majority of contouring was performed on coronal
slices as the main axis of the structure runs in the anterior–poster-
ior direction. Using the coronal plane is beneﬁcial in being able to
capture the arch of the palate and the superior, inferior and lateral
extents of the buccal mucosa. Sagittal views were useful in estab-
lishing the position of the posterior border and axial views aided in
contouring the mucosa of the retromolar trigone. The MSC were
initially delineated as a single line and, once complete, expanded
to a 3 mm annulus. The delineation process was semi-automated
using atlas-based segmentation (described in the Supplementary
Material).Comparison of geometries
The geometries of the OCC and MSC structures were compared
by measuring the volumes of these structures and the volumes of
their overlap with the primary planning target volume (PTV). To
gain an appreciation of the difference in the surface areas of the
OCC and MSC structures, an ‘OCC surface’ was deﬁned as a 3 mm
annulus extending inwards from the outer surface of the OCC.
The volumes of these ‘surface’ structures were then compared to
the MSC volumes.ottom) shown in green. The OCC representation reduces the complex shape of the
mucosal surface and, as such, represents a more anatomically realistic description of
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Comparisons of the dose distributions to the oral mucosa
extracted using the MSC method and the OCC method previously
used at our institution were performed. Neither set of contours
was used for treatment plan optimisation. All doses are quoted
as the equivalent dose in 2 Gy fractions with an a/b ratio of 10 [21].
As a result of the sparsity of dose–response studies for oral
mucosal toxicity, there is currently a lack of strong evidence on
the importance of speciﬁc dose–volume parameters for mucositis
outcomes. Clinical experience suggests that mucositis is a ‘parallel’
type toxicity. Therefore, mean dose, which incorporates informa-
tion from every dose level, is a useful descriptor of the dose dis-
tribution and so was chosen for quantitative dosimetric
comparisons. Maximum dose is included in the Supplementary
Material for completeness.Results
Structure delineation
An anatomically realistic delineation of the oral mucosa was
achieved in all patients (Fig. 1 shows a representative example
case). Eight of the 11 patients had streak artefacts on their CT scans
due to dental implants. These increased the uncertainty as to the
exact location of the mucosal surface where it was obscured by
artefact. Whilst the artefacts greatly hinder mucosal contouring
on axial slices, in the coronal and sagittal planes following the
shape of the mucosa allowed the position of obscured mucosa to
be manually imputed with relative ease. The volumes of the OCC,
OCC surface and MSC for each patient, and the overlap volume of
the OCC, OCC surface and MSC with the primary PTV are shown
in Table 1 in the Supplementary Material.Dose comparison
Using the MSC delineation method led to differences in the dose
distributions (Fig. 1 in the Supplementary Material shows a repre-
sentative example case) and dose–volume histograms compared
with the OCCmethod (Fig. 2). The median (and range) of the reduc-
tion in the mean mucosal dose when the MSC contours were used
was 28.7% (12.8–84.5%) (The individual values for all of theFig. 2. Median dose–volume histograms for the oral mucosa for the 11 patients
using the OCC (dashed line) and MSC (solid line) delineation approach. The shaded
areas represent the ranges. The darker shaded area shows the overlap between the
ranges.patients are shown in Tables 2 and 3 in the Supplementary
Material). The locations of the maximum doses, as obtained using
the OCC method, were either in the musculature of the tongue or
ﬂoor of mouth, within the PTV. These are not included in the
MSC volumes.Discussion
In this work we have demonstrated that it is possible to delin-
eate the oral mucosa of head and neck radiotherapy patients as an
anatomically realistic mucosal surface structure on planning CT
scans, rather than as an anatomically unrealistic solid organ.
There is a large difference in the geometry of the MSC, com-
pared with the OCC (Fig. 1 and Supplementary Material Table 1).
The majority of the volume difference represents the volume of
the musculature of the tongue and ﬂoor of mouth, which are not
included in the MSC. The volumes of the MSC structures are greater
than those of the corresponding OCC surface structures in all cases,
indicating that the MSC structures exhibit larger surface areas.
These volume differences translate into large differences in the
characterisations of the oral mucosal dose distributions, particu-
larly at intermediate dose levels (Fig. 2 and Supplementary
Material Fig. 1).
Reductions in the mean mucosal doses with the MSC method
were demonstrated for all patients, when compared with the
OCC method. The differences in these dose metrics between the
two contouring techniques are due to greater overlap between
the primary PTV and the OCC than the MSC (Table 1 in the
Supplementary Material). The other major source of differences
in the dose metrics is due to the MSC extending laterally, away
from the high dose region (which tends to be medially concen-
trated for the primary disease sites of patients in the study), rela-
tive to the OCC, which are centrally conﬁned. The ﬁndings of
Narayan et al. [22] give us reason to believe that the magnitudes
of the differences in the mean doses found between the two oral
mucosa outlining methods would be clinically signiﬁcant in terms
of predicting mucosal toxicity outcomes and, therefore, would also
inﬂuence radiotherapy planning interventions aimed at reducing
mucosal toxicity.
Few attempts to extract dose distributions for the oral mucosa
have previously been carried out. Sanguineti et al. deﬁned the oral
mucosa as a single solid volume encompassing the oral cavity
(including buccal mucosa), oropharynx and hypopharynx [16].
Werbrouck et al. contoured the oral cavity volume, including the
buccal mucosa, but excluded the air within the cavity [18]. van
de Water et al. studied the dose–response of the oral mucosa for
xerostomia [23], rather than mucositis. They divided the oral
mucosa into smaller substructures in an attempt to establish
which substructures, if any, are most radiosensitive for xeros-
tomia-related endpoints. A limitation of this approach is that it
does not allow for dose–area effects of the entire mucosa to be
assessed robustly.
Analysis of the treatment plans showed that the maximum
doses reported using the OCC method were located within the
musculature of the tongue or the ﬂoor of mouth in regions close
to or within the PTV. Therefore, no treatment planning interven-
tion to reduce doses to these regions would be possible without
also compromising local disease control. However, most of the oral
mucosa surface lies outside the PTV and, hence, it should be possi-
ble to achieve clinically feasible dose-sparing across at least some
of these regions. To this end, we suggest that characterising the
oral mucosa dose distribution using our new anatomically realistic
approach would provide meaningful dose information that would
allow for the modiﬁcation of treatment plans in an attempt to
reduce mucosal toxicity.
66 Novel method for oral mucosa delineationWe recognise that, within many radiotherapy treatment plan-
ning systems, it is not currently possible to perform contouring
in the coronal and sagittal planes or to construct an atlas for
semi-automated structure segmentation. Whilst contouring solely
in the axial plane would be possible by viewing the axial contours
in the coronal and sagittal planes before editing them in the axial
plane, this would be inefﬁcient. We recommend that treatment
planning system vendors make these features available in the
future, as they are necessary to accurately contour structures with
complex shapes.
The method we have developed for oral mucosal surface outlin-
ing provides a means of obtaining a more anatomically representa-
tive characterisation of the dose distribution delivered to the oral
mucosa surfaces than has previously been achieved. This will
enable the acquisition of higher quality dosimetric data for use in
future studies of oral mucositis dose–response.
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